Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3600
+0.0080 (2.27%)
Nov 26, 2025, 4:00 PM EST - Market closed
Vaxart Revenue
Vaxart had revenue of $72.41M in the quarter ending September 30, 2025, with 1,367.93% growth. This brings the company's revenue in the last twelve months to $148.20M, up 784.27% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$148.20M
Revenue Growth
+784.27%
P/S Ratio
0.55
Revenue / Employee
$1,411,467
Employees
105
Market Cap
86.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
| Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
| Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
| Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
| Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VXRT News
- 8 days ago - Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript - Seeking Alpha
- 13 days ago - Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Vaxart to Host Upcoming Conference Calls - GlobeNewsWire
- 22 days ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 22 days ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 7 weeks ago - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewsWire
- 2 months ago - Vaxart Appoints W. Mark Watson as Lead Independent Director - GlobeNewsWire
- 2 months ago - Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire